Print this page
Radiation
-
Targeted Genomic Analysis of Human Cancers.
Protocol: 001209Principal Investigator:
- Shridar Ganesan
Applicable Disease Sites: Any Site -
Targeted Genomic Analysis of Human Cancers.
Protocol: 001209Principal Investigator:
- Shridar Ganesan
Applicable Disease Sites: Any Site -
A Prospective Registry of Spine Cancer Patients Undergoing Surgical decompression followed by Radiation Therapy for Spine Tumors
Protocol: 002575Principal Investigator:
- Jonathan Sherman
Applicable Disease Sites: Brain and Nervous System -
Assessing Collaborations Between Radiation Oncologists and Population
Scientists
Protocol: 002577Applicable Disease Sites: Any Site
-
A Prospective Registry of Spine Cancer Patients Undergoing Surgical decompression followed by Radiation Therapy for Spine Tumors
Protocol: 002575Principal Investigator:
- Jonathan Sherman
Applicable Disease Sites: Brain and Nervous System -
Assessing Collaborations Between Radiation Oncologists and Population
Scientists
Protocol: 002577Applicable Disease Sites: Any Site
-
Study Protocol Cancer in Pregnancy (CIP-study)
Protocol: 012201Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Any Site
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Study Protocol Cancer in Pregnancy (CIP-study)
Protocol: 012201Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Any Site
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies.
Protocol: 012408Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies.
Protocol: 012408Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma